Venous Thromboembolism
📧 Sign up to get email alerts when something new happens for Venous Thromboembolism.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-12-06Clinical Trial Update: Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma [Phase 4]
Phase 4 trial update on apixaban for primary prevention of venous thromboembolism in patients with multiple myeloma; results have been poste…
-
FDA approval · 2019-11-20FDA Approved: HEPARIN SODIUM — Supplemental Application (Gland Pharma Limited)
FDA approved a supplemental application for Heparin Sodium from Gland Pharma Limited (ANDA205323). This action confirms continued availabili…
-
CLINICAL_TRIALS trial_result · 2019-11-19Clinical Trial Update: A Prospective Study in Chinese Patients With Lower Extremity Ankle Fracture of Oral Anticoagulants to Prevent Venous Thromboembolism (VTE) [Phase 4]
Phase 4 trial in Chinese patients evaluating oral anticoagulants for prevention of venous thromboembolism after lower extremity ankle fractu…
-
CLINICAL_TRIALS trial_result · 2019-11-19Clinical Trial Update: Aspirin and Enoxaparin for VTE in Trauma [Phase 4]
Phase 4 clinical trial investigating aspirin and enoxaparin for venous thromboembolism prevention in trauma patients has been terminated wit…
-
FDA approval · 2019-10-31FDA Approved: WARFARIN SODIUM — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for Warfarin Sodium (Warfarin) from Amneal Pharmaceuticals LLC.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA withdrawal · 2019-10-24EMA Lapsed: Thorinane (enoxaparin sodium) — Pharmathen S.A.
EMA has lapsed the marketing authorisation for Thorinane (enoxaparin sodium) by Pharmathen S.A., with the therapeutic area being venous thro…
-
CLINICAL_TRIALS trial_result · 2019-10-21Clinical Trial Update: Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia [Phase 2]
Phase 2 clinical trial assessing management of platelet transfusion therapy in patients with blood cancers or treatment-induced thrombocytop…
-
FDA approval · 2019-09-26FDA Approved: WARFARIN SODIUM — Supplemental Application (Exelan Pharmaceuticals Inc.)
The FDA approved a supplemental application for Warfarin Sodium by Exelan Pharmaceuticals. This action updates the regulatory status of this…
-
FDA approval · 2019-09-20FDA Approved: JANTOVEN — Supplemental Application (Upsher-Smith Laboratories, LLC)
The FDA approved a supplemental application for JANTOVEN (warfarin sodium) submitted by Upsher-Smith Laboratories, LLC.
-
CLINICAL_TRIALS trial_result · 2019-09-12Clinical Trial Update: ODEN Trial: Option vs. Denali IVC Filters [NA]
A terminated randomized trial comparing ODEN and Denali inferior vena cava filters for venous thromboembolism; results posted in 2019.
-
FDA approval · 2019-08-23FDA Approved: XARELTO — Supplemental Application (Janssen Pharmaceuticals, Inc.)
FDA approved a supplemental application for XARELTO (rivaroxaban) filed by Janssen Pharmaceuticals, resulting in labeling changes to the pro…
-
CLINICAL_TRIALS withdrawal · 2019-08-16Clinical Trial Update: Timing of VTE Prophylaxis in TBI [Phase 4]
A Phase 4 trial evaluating timing of VTE prophylaxis in traumatic brain injury has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2019-08-14Clinical Trial Update: Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism [Phase 4]
A Phase 4 trial comparing oral anticoagulants for extended venous thromboembolism was terminated; results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-06-24Clinical Trial Update: Evaluation of Anti-Xa Levels in Surgery Patients Receiving Fixed Dose Heparin [EARLY_Phase 1]
A Phase Early 1 trial evaluating anti-Xa level monitoring in surgery patients on fixed-dose heparin has completed with results posted.
-
FDA approval · 2019-05-28FDA Approved: HEPARIN SODIUM — Original Application (Meitheal Pharmaceuticals Inc.)
FDA approved Meitheal Pharmaceuticals Inc.'s Heparin Sodium as an Original Application (ANDA 211007), making a generic injectable anticoagul…
-
CLINICAL_TRIALS research · 2019-05-17Clinical Trial Update: Educating Nurses About Venous Thromboembolism (VTE) Prevention [NA]
A completed clinical trial focused on educating nurses about venous thromboembolism (VTE) prevention.
-
CLINICAL_TRIALS trial_result · 2019-05-14Clinical Trial Update: Thromboprophylaxis After Surgery for Gynecologic Malignancy in China [Phase 3]
Phase 3 trial assessing thromboprophylaxis after gynecologic cancer surgery in China; completed study on venous thromboembolism prevention w…
-
CLINICAL_TRIALS trial_result · 2019-04-17Clinical Trial Update: A Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism [Phase 3]
A Phase 3 trial evaluating dabigatran etexilate as the primary treatment for malignancy-associated venous thromboembolism is underway, with …
-
CLINICAL_TRIALS trial_result · 2019-04-16Clinical Trial Update: Improving Anticoagulation Control in VISN 1 [NA]
A completed clinical trial update from VA exploring improved anticoagulation control for patients using anticoagulants, including those with…
-
CLINICAL_TRIALS trial_result · 2019-04-16Clinical Trial Update: Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients [Phase 2]
Phase 2 clinical trial update for Fragmin (dalteparin) in treating acute venous thromboembolism in pediatric cancer patients has completed w…
-
CLINICAL_TRIALS trial_result · 2019-01-31Clinical Trial Update: Distribution of Risk Factors for Venous Thromboembolism in Blood Donors
This completed clinical trial analyzes the distribution of risk factors for venous thromboembolism in blood donors. It examines whether bloo…
-
FDA approval · 2018-12-20FDA Approved: HEPARIN SODIUM AND DEXTROSE — Supplemental Application (Hospira, Inc.)
FDA approved a supplemental application for Hospira's Heparin Sodium and Dextrose (heparin sodium) product, authorizing changes under the ND…
-
FDA approval · 2018-12-14FDA Approved: HEPARIN SODIUM — Original Application (NorthStar RxLLC)
The FDA approved NorthStar RxLLC's original application for generic heparin sodium (ANDA211005).
-
CLINICAL_TRIALS trial_result · 2018-11-20Clinical Trial Update: Apixaban for the Prevention of Venous Thromboembolism in Cancer Patients [Phase 2]
Phase 2 trial update evaluating apixaban for prevention of venous thromboembolism in cancer patients has completed.
-
CLINICAL_TRIALS trial_result · 2018-10-24Clinical Trial Update: Cancer Venous Thromboembolism (VTE) [Phase 3]
Phase 3 clinical trial update for cancer-associated venous thromboembolism (VTE) completed with results posted in 2018.